Avita Medical (RCEL)
(Real Time Quote from BATS)
$5.25 USD
-0.03 (-0.57%)
Updated Aug 6, 2025 12:50 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RCEL 5.25 -0.03(-0.57%)
Will RCEL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RCEL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RCEL
Does Avita Medical (RCEL) Have the Potential to Rally 73.72% as Wall Street Analysts Expect?
Wall Street Analysts Predict a 52.64% Upside in Avita Medical (RCEL): Here's What You Should Know
RCEL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for RCEL
AVITA Medical to Announce Second Quarter 2025 Financial Results | RCEL Stock News
Notable Tuesday Option Activity: RCEL, RYAM, SOFI
Top 3 Health Care Stocks You'll Regret Missing This Quarter
AVITA Medical (RCEL) Receives Continued 'Buy' Rating from D. Boral Capital | RCEL Stock News
TD Cowen Sticks to Its Buy Rating for Avita Medical (RCEL)